IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer

• Casitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase that has been shown to be a key regulator of the activation of T and natural killer (NK) cells in the absence of CD28 costimulation

• GRC 65327 has been identified by IGI as a novel, nanomolar potent, selective, and orally bioavailable Cbl/b inhibitor

New York, October 15, 2024: Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully integrated clinical-stage biotech company developing multispecifics™ in oncology, and Glenmark Pharmaceuticals Ltd., today announced a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH) in the United States.

Under the CRADA, IGI and NCI will collaborate on evaluating IGI’s proprietary Cbl/b small molecule, GRC 65327. “GRC 65327 is a best-in-class, novel, selective, orally active, Cbl-b inhibitor that demonstrates good in vitro potency, in vivo efficacy and an acceptable non-clinical toxicity profile,” said Nagaraj Gowda, PhD, Vice-President, Head of Small Molecule Research at IGI.

In the research covered by the CRADA, NCI will first characterize and then test GRC 65327 in immune-competent models of triple-negative breast cancer (TNBC) with the intent of generating preclinical data to support a clinical trial in late-stage TNBC at NCI. Stan Lipkowitz, M.D., Ph.D., Chief of Women’s Malignancies Branch, Deputy Director of the Center for Cancer Research at the NCI, and his team will build on their substantial achievements in early Cbl/b research that include initially cloning the gene and having identified Cbl/b’s role as a negative regulator of the adaptive immune system.

“Small molecule inhibitors of Cbl/b may enhance adaptive anti-tumor activity by increased signaling through the costimulatory pathway in T cells and innate immunity via enhanced NK cell activity,” said Dr. Lipkowitz. “My group will test the novel Cbl/b inhibitor developed by IGI in in vitro, cell-based, and in vivo mammary cancer models to evaluate its activity as Cbl/b inhibitors and modulators of adaptive and innate immune response to breast cancers.”

“We believe in the power of collaboration to drive innovation. Partnering with Dr. Lipkowitz and the NCI to advance our scientific understanding of GRC 65327 is expected to speed its potential development in TNBC, a cancer with few effective treatment options for patients,” said Cyril Konto, M.D., President, Executive Director and CEO of IGI. “In addition, the work of Dr. Lipkowitz’s laboratory in late-stage TNBC complements the program IGI has developed to advance GRC 65327 in other solid tumors.”

Corporate Comm India (CCI Newswire)